NIMH Fact Sheet
Post-Traumatic Stress Disorder Research
What is Post-Traumatic Stress Disorder?
Post-traumatic stress disorder (PTSD) is an anxiety
disorder that some people develop after seeing or
living through an event that caused or threatened
serious harm or death. Symptoms include
flashbacks or bad dreams, emotional numbness,
intense guilt or worry, angry outbursts, feeling
“on edge,” or avoiding thoughts and situations
that remind them of the trauma. In PTSD, these
symptoms last at least
one month.
To aid those who suffer with PTSD, the National
Institute of Mental Health (NIMH) is supporting
PTSD-focused research, and related studies on
anxiety and fear, to find better ways of helping
people cope with trauma, as well as better ways
to treat and ultimately prevent the disorder.
This research fact sheet will highlight several
important areas that NIMH researchers have
recently learned about:
possible risk factors,
treating the disorder, and
next steps for PTSD research.
For more information about PTSD, please see the
NIMH Post-Traumatic Stress Disorder booklet.
You can also find a list of places to find more
information about PTSD and NIMH at the end of
this fact sheet.
Research on Possible Risk Factors for PTSD
Currently, many scientists are focusing on genes
that play a role in creating fear memories.
Understanding how fear memories are created
may help to refine or find new interventions for
reducing the symptoms of PTSD. For example,
PTSD researchers have pinpointed genes
that make:
Stathmin, a protein needed to form fear
memories. In one study, mice that did not
make stathmin were less likely than normal
mice to “freeze,” a natural, protective
response to danger, after being exposed to
a fearful experience. They also showed less
innate fear by exploring open spaces more
willingly than normal mice.1
GRP (gastrin-releasing peptide), a signaling
chemical in the brain released during
emotional events. In mice, GRP seems to
help control the fear response, and lack of
GRP may lead to the creation of greater and
more lasting memories of fear.2

Researchers have also found a version of the 5-
HTTLPR gene, which controls levels of serotonin—
a brain chemical related to mood—that appears
to fuel the fear response.3 Like other mental
disorders, it is likely that many genes with small
effects are at work in PTSD.
Studying parts of the brain involved in dealing
with fear and stress also helps researchers to
better understand possible causes of PTSD. One
such brain structure is the amygdala, known for
its role in emotion, learning, and memory. The
amygdala appears to be active in fear acquisition,
or learning to fear an event (such as touching a
hot stove), as well as in the early stages of fear
extinction, or learning not to fear.4
Storing extinction memories and dampening
the original fear response appears to involve the
prefrontal cortex (PFC) area of the brain,4
involved in tasks such as decision-making,
•
•
•
U.S. Department of Health & Human Services • National Institutes of Health • National Institute of Mental Health
•
•
1/5
problem-solving, and judgment. Certain areas of
the PFC play slightly different roles. For example,
when it deems a source of stress controllable, the
medial PFC suppresses an alarm center deep in
the brainstem and controls the stress response.5
The ventromedial PFC helps sustain long-term
extinction of fearful memories, and the size of
this brain area may affect its ability to do so.6
Individual differences in these genes or brain
areas may only set the stage for PTSD without
actually causing symptoms. Environmental
factors, such as childhood trauma, head injury, or
a history of mental illness, may further increase a
person’s risk by affecting the early growth of the
brain.7 Also, personality and cognitive factors,
such as optimism and the tendency to view
challenges in a positive or negative way, as well
as social factors, such as the availability and use
of social support, appear to influence how people
adjust to trauma.8 More research may show what
combinations of these or perhaps other factors
could be used someday to predict who will
develop PTSD following a traumatic event.
NIMH Fact Sheet
Post-Traumatic Stress Disorder Research
2/5
Amygdala
Prefrontal
cortex
Ventromedial
prefrontal cortex
Medial
prefrontal cortex
Brain Structures Involved in Dealing with
Fear and Stress
Research on Treating PTSD
Currently, people with PTSD may be treated with
psychotherapy (“talk” therapy), medications, or a
combination of the two.
Psychotherapy
Cognitive behavioral therapy (CBT) teaches
different ways of thinking and reacting to the
frightening events that trigger PTSD symptoms
and can help bring those symptoms under
control. There are several types of CBT, including:

exposure therapy – uses mental imagery,
writing, or visiting the scene of a trauma
to help survivors face and gain control of
overwhelming fear and distress.
cognitive restructuring – encourages
survivors to talk about upsetting (often
incorrect) thoughts about the trauma,
question those thoughts, and replace them
with more balanced and correct ones.
stress inoculation training – teaches anxiety
reduction techniques and coping skills to
reduce PTSD symptosm, and helps correct
inaccurate thoughts related to the trauma.
NIMH is currently studying how the brain
responds to CBT compared to sertraline (Zoloft),
one of the two medications recommended
and approved by the U.S. Food and Drug
Administration (FDA) for treating PTSD. This
research may help clarify why some people
respond well to medication and others
to psychotherapy.
Medications
In a small study, NIMH researchers recently found
that for people already taking a bedtime dose
of the medication prazosin (Minipress), adding
a daytime dose helped to reduce overall PTSD
symptom severity, as well as stressful responses to
trauma reminders.9
•
•
•
NIH Medical Arts
Another medication of interest is D-cycloserine
(Seromycin), which boosts the activity of a brain
chemical called NMDA, which is needed for fear
extinction. In a study of 28 people with a fear
of heights, scientists found that those treated
with D-cycloserine before exposure therapy
showed reduced fear during the therapy sessions
compared to those who did not receive the
drug.10 Researchers are currently studying the
effects of using D-cycloserine with therapy to
treat PTSD.
Propranolol (Inderal), a type of medicine called a
beta-blocker, is also being studied to see if it may
help reduce stress following a traumatic event
and interrupt the creation of fearful memories.
Early studies have successfully reduced or
seemingly prevented PTSD in small numbers of
trauma victims.11
Treatment After Mass Trauma
NIMH researchers are testing creative approaches
to making CBT widely available, such as with
Internet-based self-help therapy and telephone-
assisted therapy. Less formal treatments for those
experiencing acute stress reactions are also being
explored to reduce chances of developing full
blown PTSD.
For example, in one preliminary study, researchers
created a self-help website using concepts of
stress inoculation training. People with PTSD
first met face-to-face with a therapist. After this
meeting, participants could log onto the website
to find more information about PTSD and ways
to cope, and their therapists could also log on to
give advice or coaching as needed. Overall, the
scientists found delivering therapy this way to be
a promising method for reaching a large number
of people suffering with PTSD symptoms.12
Researchers are also working to improve methods
of screening, providing early treatment, and
tracking mass trauma survivors; and approaches
for guiding survivors through self-evaluation/
NIMH Fact Sheet
Post-Traumatic Stress Disorder Research
3/5
screening and prompting referral to mental
health care providers based on need.
The Next Steps for PTSD Research
In the last decade, rapid progress in research on
the mental and biological foundations of PTSD
has lead scientists to focus on prevention as a
realistic and important goal.
For example, NIMH-funded researchers are
exploring new and orphan medications thought
to target underlying causes of PTSD in an
effort to prevent the disorder. Other research is
attempting to enhance cognitive, personality,
and social protective factors and to minimize risk
factors to ward off full-blown PTSD after trauma.
Still other research is attempting to identify what
factors determine whether someone with PTSD
will respond well to one type of intervention or
another, aiming to develop more personalized,
effective, and efficient treatments.
The examples described here are only a small
sampling of the ongoing work at NIMH. To
find more information about ongoing PTSD
clinical studies, see NIMH’s PTSD clinical trials
webpage at http://www.nimh.nih.gov/studies/
studies_ct.cfm?id=11. As gene research and
brain imaging technologies continue to improve,
scientists are more likely to be able to pinpoint
when and where in the brain PTSD begins. This
understanding may then lead to better targeted
treatments to suit each person’s own needs or
even prevent the disorder before it causes harm.
Where Can I Get More Information?
MedlinePlus, a service of the U.S. National Library
of Medicine and the National Institutes of Health,
provides updated information and resource lists
for many health topics. Find out more about
PTSD at:
http://www.nlm.nih.gov/medlineplus/
posttraumaticstressdisorder.html.
cortex determines how stressor
controllability affects behavior and
dorsal raphe nucleus. Nat Neurosci. Mar
2005;8(3):365-371.
6.
Milad MR, Quinn BT, Pitman RK, Orr
SP, Fischl B, Rauch SL. Thickness of
ventromedial prefrontal cortex in
humans is correlated with extinction
memory. Proc Natl Acad Sci U S A. Jul 26
2005;102(30):10706-10711.
7.
Gurvits TV, Gilbertson MW, Lasko NB,
et al. Neurologic soft signs in chronic
posttraumatic stress disorder. Arch Gen
Psychiatry. Feb 2000;57(2):181-186.
8.
Brewin CR. Risk factor effect sizes in
PTSD: what this means for intervention. J
Trauma Dissociation. 2005;6(2):123-130.
9.
Taylor FB, Lowe K, Thompson C, et al.
Daytime Prazosin Reduces Psychological
Distress to Trauma Specific Cues in
Civilian Trauma Posttraumatic Stress
Disorder. Biol Psychiatry. Feb 3 2006.
10.
Ressler KJ, Rothbaum BO, Tannenbaum
L, et al. Cognitive enhancers as adjuncts




to psychotherapy: use of D-cycloserine in
phobic individuals to facilitate extinction
of fear. Arch Gen Psychiatry. Nov
2004;61(11):1136-1144.
11.
Pitman RK, Sanders KM, Zusman RM, et
al. Pilot study of secondary prevention
of posttraumatic stress disorder with
propranolol. Biol Psychiatry. Jan 15
2002;51(2):189-192.
12.
Litz BT WL, Wang J, Bryant R, Engel CC.
A therapist-assisted Internet self-help
program for traumatic stress. Prof Psychol
Res Pr. December 2004;35(6):628-634.
En Español:
http://www.nlm.nih.gov/medlineplus/spanish/
posttraumaticstressdisorder.html.
Information from NIMH is available online, in PDF,
or as paper brochures sent through the mail. If
you would like to have NIMH publications, you
can order them at http://www.nimh.nih.gov or
contact NIMH at the numbers listed below.
National Institute of Mental Health
Office of Science Policy, Planning, and Communications
6001 Executive Boulevard
Room 8184, MSC 9663
Bethesda, MD 20892-9663
Phone: 301-443- 4513
Toll-free Voice: 1-866-615-NIMH (6464)
TTY: 1-866-415-8051 toll free
Fax: 301-443-4279
E-mail: nimhinfo@nih.gov
References
1.
Shumyatsky GP, Malleret G, Shin
RM, et al. stathmin, a Gene Enriched
in the Amygdala, Controls Both
Learned and Innate Fear. Cell. Nov 18
2005;123(4):697-709.
2.
Shumyatsky GP, Tsvetkov E, Malleret G, et
al. Identification of a signaling network
in lateral nucleus of amygdala important
for inhibiting memory specifically
related to learned fear. Cell. Dec 13
2002;111(6):905-918.
3.
Hariri AR, Mattay VS, Tessitore A,
et al. Serotonin transporter genetic
variation and the response of the
human amygdala. Science. Jul 19
2002;297(5580):400-403.
4.
Milad MR, Quirk GJ. Neurons in medial
prefrontal cortex signal memory
for fear extinction. Nature. Nov 7
2002;420(6911):70-74.
5.
Amat J, Baratta MV, Paul E, Bland ST,
Watkins LR, Maier SF. Medial prefrontal
4/5
NIMH Fact Sheet
Post-Traumatic Stress Disorder Research

NIMH publications are in the public domain and may be reproduced or copied without the permission from the
National Institute of Mental Health (NIMH). NIMH encourages you to reproduce them and use them in your
efforts to improve public health. Citation of the National Institute of Mental Health as a source is appreciated.
However, using government materials inappropriately can raise legal or ethical concerns, so we ask you to use
these guidelines:
NIMH does not endorse or recommend any commercial products, processes, or services, and publications may
not be used for advertising or endorsement purposes.
NIMH does not provide specific medical advice or treatment recommendations or referrals; these materials may
not be used in a manner that has the appearance of such information.
NIMH requests that non-Federal organizations not alter publications in a way that will jeopardize the integrity
and "brand" when using publications.
Addition of Non-Federal Government logos and website links may not have the appearance of NIMH
endorsement of any specific commercial products or services or medical treatments
or services.
If you have questions regarding these guidelines and use of NIMH publications, please contact the NIMH
Information Center at 1-866-615-6464 or at nimhinfo@nih.gov.
NIMH Fact Sheet
Post-Traumatic Stress Disorder Research
5/5